HK shares of WuXi Bio, WuXi AppTec jump on report cos explore sale of pharma operations
** Hong Kong-listed shares of WuXi Biologics 2269.HK jump 8.3% to HK$20.30, and are third-biggest pct gainers in the benchmark Hang Seng Index .HSI
** WuXi Biologics and WuXi AppTec 603259.SS are planning to sell some of their operations after the Chinese biotech companies were targeted by the U.S. on national security grounds, the Financial Times reported on Thursday
** WuXi Biologics and WuXi AppTec did not immediately respond to Reuters' requests for a comment
** The U.S. House of Representatives passed a bill last month aiming to restrict business with China's WuXi AppTec and several other biotech companies on national security grounds
** Hong Kong stock of WuXi AppTec 2359.HK jumps 7.3% to HK$64.55, and is fourth-biggest pct gainer in Hang Seng Index .HSI, which is up 0.4%
** Hang Seng Commerce & Industry Index .HSNC gains 0.8%, and healthcare index .HSCIH rises 1.7%
Reporting by Donny Kwok
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
